SEOUL: South Korea approved the first domestically created COVID-19 vaccine, manufactured by SK bioscience, for general public use following positive clinical information, authorities said on Wednesday (Jun 29).
The particular SKYCovione vaccine was authorised for a two-dose regimen on individuals aged 18 or older, with photos given four weeks aside, according to the Ministry associated with Food and Drug Safety.
In a stage III clinical trial of 4, 037 adults, SKYCovione caused neutralising antibody responses against the SARS-CoV-2 parent strain, SK bioscience said in a statement.
It is not yet known how effective it is against Omicron and other COVID-19 versions.
The shot was jointly developed by the University associated with Washington’s Institute with regard to Protein Design, using the support of global drugmaker GlaxoSmithKline (GSK).
SK bioscience said it would look for authorisations for distribution of SKYCovione far away and through worldwide vaccine sharing service COVAX, and for emergency use listing on the World Health Organization.
South Korean authorities have agreed to a 200 billion won (US$155 million) deal to buy ten million doses from the vaccine, which can be kept under normal refrigeration conditions, and formerly said they anticipated it to be folded out from the second 1 / 2 of the year.
SK bioscience is now looking at its possible use with regard to booster shots, and planning trials pertaining to adolescents and children, it added.
Nearly 87 per cent of South Korea’s 52 million human population are fully vaccinated, with 65 per cent having also had a booster shot, according to the Korea Disease Manage and Prevention Agency data.
Reading more on: https://www.channelnewsasia.com/asia/south-korea-approves-first-domestically-developed-covid-19-vaccine-sk-bioscience-2776721